Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing therapeutic solutions for cancer and various other proliferative disorders. At the forefront of its pipeline are several investigational therapies: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is currently undergoing Phase 1/2 clinical evaluation. It's being assessed as a monotherapy for solid tumors and in combination with venetoclax for managing relapsed or refractory chronic lymphocytic leukemia.